| Home Market Dynamics You and Market Sector Analysis Company Insights AI Investing About Contact Us Login |
| The price action of Health Care (XLV) sector is shaped by numerous forces, ranging from broad macroeconomic trends to company-specific performance and market structure. The overall sentiment for Health Care sector is very positive (overall 5, positive 5, negative 0) on 20251113. The forces of Sentiment towards Fundamentals (2.4), Valuation Sentiment (2.1), Price Level (2), Sector Price Trend (1.6), Option Speculation (1.5), Broad Market Trend (0.4), and Market Risk Prefrence (0) will drive up the price. The forces of and Market Risk Prefrence (0) will drive down the price. 'Buy the dips' is the preferred trading strategy. Hourly SMA 20 trend line is likely to provide a support from any pullbacks. The swing to upside will be significant considering the high positive sentiment forces (5). The extreme bullish overall sentiment (5) may signal the top of this uptrend. The sentiment for Broad Market Trend is calculated based on SPY trend. The sentiment for Sector Price Trend is calculated based on XLV trend. The sentiment for Option Speculation is calculated from put/call ratio. The Risk Prefrence is calculated from Bitcoin price trend. Price Level sentiment is positive when oversold, and negative when overbought. Valuation Sentiment, and Sentimentals towards Fundamentals are extracted from headlines and market commentary. All sentiment scores are normalized on a -10 - +10 scale. |
| Date | Attention | Average Attention | Price | Price Level | Change | SMA10 Trend | Market Sentiment | Trend Sentiment | Fundamentals | News Sentiment |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025-11-13 | 1% | 0.9% | 152.77 | 112 | -0.03% | 0.61% | 3.1 | 1.6 | 2.4 | -0.2 |
| 2025-11-12 | 1% | 1% | 152.81 | 126 | 1.4% | 0.55% | 3.5 | 1.6 | 2.2 | 2.2 |
| 2025-11-11 | 1% | 1.1% | 150.69 | 126 | 2.32% | 0.41% | 3.1 | 0.9 | 2.2 | 2.2 |
| 2025-11-10 | 1% | 1.4% | 147.28 | 93 | 0.79% | 0.07% | 2.9 | 0.6 | 2.1 | -1.9 |
| 2025-11-09 | 0% | 1.6% | 3.8 | 0.5 | 2.1 | 8 | ||||
| 2025-11-08 | 1% | 1.7% | 3.4 | 0.5 | 2.1 | 7 | ||||
| 2025-11-07 | 1% | 1.7% | 146.12 | 77 | 0.14% | 0% | 0.8 | 0.5 | 2.1 | -0.6 |
| 2025-11-06 | 2% | 1.9% | 145.92 | 76 | 0.19% | -0.07% | 0.4 | 0.3 | 1.8 | 2.4 |
| 2025-11-05 | 2% | 2% | 145.64 | 74 | 0.43% | 0% | 0.7 | 0.1 | 1.9 | 1.2 |
| 2025-11-04 | 3% | 1.9% | 145.01 | 65 | 0.42% | 0% | 0.6 | -0.1 | 1.9 | 4.4 |
| Both emotion scores and sentiment scores are calculated in a -10 - +10 scale. | The price level reaches 100 at Bollinger upper band, and zero at lower band. |
| 1 (-5) Hapvida Owners Boost Stakes After Earnings Miss Triggers Rout The controlling shareholders of Brazil’s Hapvida Participacoes e Investimentos SA are increasing their stakes in the health care operator after disappointing earnings triggered the company’s worst selloff since it went public in 2018. (https://www.bloomberg.com/) Thu. Nov 13, 2025 | |
| 2 (8) Pfizer CEO Albert Bourla says aggressive bid for Metsera reflects company's 'right to win' obesity market Pfizer CEO Albert Bourla told Yahoo Finance that Pfizer has a "right to win" on the obesity drugs that have become a major market. (https://finance.yahoo.com/) Thu. Nov 13, 2025 | |
| 3 (-2) Money Moving Into Healthcare Not AI; Four Fed Presidents Do Not Want a Rate Cut; Euphoria Wearing Off Rotating To Healthcare Please click here for an enlarged chart comparing Invesco QQQ Trust Series 1 (NASDAQ: (https://www.benzinga.com/) Thu. Nov 13, 2025 | |
| 4 (-2) Elevance Seeks to Keep NYC Contract in Secretive Legal Fight Elevance Health Inc. is trying to keep a major contract to provide health benefits for New York City public employees by arguing the city was “arbitrary and capricious” when it gave the lucrative award to its rivals. (https://www.bloomberg.com/) Thu. Nov 13, 2025 | |
| 5 (-2) The Fight to Save the $2.7 Billion Botox Empire Competition and the “natural look” have created a perfect storm. (https://www.bloomberg.com/) Thu. Nov 13, 2025 | |
| 6 (2) Cheaper medicines, free beach trips: U.S. health plans tap prescriptions that feds say are illegal AFPs promise to connect patients with more-affordable options for accessing specialty medications that often come at very high costs. There's a major catch. (https://www.cnbc.com/) Thu. Nov 13, 2025 | |
| 7 (8) Inside This Startup's Solution To An $80 Billion Healthcare Problem Bold Cofounder and CEO Amanda Rees sits down with ForbesWomen editor Maggie McGrath to discuss her company's model aimed at improving the "healthspan" of aging adults. (https://www.forbes.com/) Wed. Nov 12, 2025 | |
| 8 (7) AbbVie Shares Rise To Intraday High After Key Trading Signal A key trading signal flashed for AbbVie shares at a price of $228.47, after which ABBV rose as much as 2.4% to an intraday high of $233.90. (https://www.benzinga.com/) Wed. Nov 12, 2025 | |
| 9 (4) Siemens to Hand €15 Billion Stake in MRI Maker to Investors Siemens AG will hand a 30% stake in Siemens Healthineers AG to its own shareholders, allowing it to reduce its exposure to the medical technology business and focus on software. (https://www.bloomberg.com/) Wed. Nov 12, 2025 | |
| 10 (-2) Senate Punts On Health Insurance Subsidies To End Shutdown In this week’s edition of InnovationRx, we look at BillionToOne’s IPO, China’s biotech power couple and Lilly’s eye drug deal. (https://www.forbes.com/) Wed. Nov 12, 2025 | |
| 11 (7) Healthy Returns: Novo Nordisk boosts the case for its upcoming obesity pill with additional data Novo Nordisk released new data to underscore its pill's safety and effectiveness, while Trump is asked whether private plans could see lower GLP-1 costs. (https://www.cnbc.com/) Wed. Nov 12, 2025 | |
| 12 (8) Alkermes Eyes Global Phase 3 Trial After Encouraging Data From Sleep Disorder Study Alkermes' alixorexton met key goals in a phase 2 study for narcolepsy type 2, showing significant improvements in wakefulness and sleepiness scores. (https://www.benzinga.com/) Wed. Nov 12, 2025 | |
| 13 (2) Pfizer: Could AI unlock new value for drug makers? Pfizer (PFE) managed to outbid competitor Novo Nordisk (NVO) to acquire Metsera (MTSR) in a deal valued at up to $10 billion. Pfizer stock is down by nearly 3% from this time a year ago. Robinhood (HOOD) Chief Investment Officer Stephanie Guild and Yahoo Finance senior reporters Brooke DiPalma and Ines Ferré discuss Pfizer's position in the healthcare space (XLV) and whether artificial intelligence could unlock new growth prospects for the pharmaceutical industry. Tune in on Thursday, November 13, for Yahoo Finance's interview with Pfizer CEO Albert Bourla at Yahoo Finance Invest. To watch more expert insights and analysis on the latest market action, check out more Opening Bid. (https://finance.yahoo.com/) Wed. Nov 12, 2025 | |
| 14 (-2) Eli Lilly Drops CVS Health's Drug Benefit Plan For Employees Ahead Of 2026 Switch Eli Lilly to drop CVS Health's drug benefit plan and move to Rightway in 2026 as Novo Nordisk cuts Wegovy prices in India to defend market share. (https://www.benzinga.com/) Wed. Nov 12, 2025 | |
| 15 (-5) DexCom Stock Just Fell to a 5-Year Low. Is It a No-Brainer Buy at This Price? DexCom's growth rate has been improving, but that hasn't been enough of a reason for investors to buy up the stock. (https://www.fool.com/) Wed. Nov 12, 2025 | |
| 16 (-5) Lilly Drops CVS Drug Plan for Workers After Novo Obesity Deal Eli Lilly & Co. is dropping CVS Health Corp’s drug benefit plan for its employees after CVS stopped covering its blockbuster weight-loss drug in favor of a rival medication from Novo Nordisk A/S, according to people familiar with the matter. (https://www.bloomberg.com/) Wed. Nov 12, 2025 | |
About
Contact Us
Copyright ©2025 TheMarketUnfolds. All rights reserved. Denver, Colorado, USA